Lorvotuzumab mertansine: Additional Phase I data

Data from 39 evaluable patients in an expansion cohort of the open-label, dose-escalation, U.S. Phase I Study 005 trial showed that once-weekly 75 mg/m 2 IMGN901 for 3 weeks of a 4-week cycle plus lenalidomide and dexamethasone led to a clinical response rate, defined as a minimal response or better, of 64%. Additionally, 31% of patients had stable disease and 31% had a very good partial response or better. In lenalidomide-naïve patients (n=16), there were 14 partial responses or better and 2 cases of stable disease. In patients previously treated with lenalidomide (n=23), there were 3 very good partial responses, 5 partial responses, 3 minimal responses and 10 cases of stable disease. Median time to progression was 7.7 months. Data were presented at the American Society of Hematology meeting in Atlanta. ...